The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
7.448p per £100 000,000 once the new shares are admitted before the maths police turn up and correct me. :)
This is so under the radar at the moment you've got to pinch yourself
8.9p I meant.
I dont want to get accused of crazy prices and ramping like what was mentioned on here yesterday so my valuation of imutex was based on a take over of £500,000,000. Its 4.9p per share at £100,000,000 at 49%
Yes i had shares already
Jizjoz were you an existing share holder of OO? Just seen it's your first post here that's all. GL anyway
I was too late to subscribe to thIs one , but based on previous primary bid allocations it was the Monday week following a weekend offering. However you may need to talk to your broker to find your shares and encourage them to allocate them to your account.
Hi
Can anyone tell me when i will receive the 11p sharesfrom primary bid?
No, they do not have the IP being the challenge model or the quarantine facilities. Only orph have carry out on any scale
they would have to build a quarentine unit and develop a complete challange study model from scratch which takes huge investment and a long time to do...Hence why Cathal is so excited by this part of the business
If Astra are working on the vaccine with Oxford University, won't they just use the lab facilities at Oxford to do the challenge trials?..
Also in the Times
https://www.thetimes.co.uk/edition/news/coronavirus-vaccine-trial-may-need-to-infect-people-7nqbrjbq5
This is definitely coming to Orph
Other vaccine makers may have to use this if the COVID 19 becomes too low in the populations. This means the volunteers will be exposed to the virus. Found from the article above.
https://uk.mobile.reuters.com/article/amp/idUKKBN2342CC
Astrazenica suggest doing Human Challenge studies to prove vaccines effectiveness. Which is one of the arms of Open Orphan.
So-called human challenge trials have been discussed as an alternative option by scientists, whereby vaccinated volunteers are infected intentionally.
"We are running against time. We are seeing already in Europe the disease is declining," Soriot told an online press briefing. "Very soon the disease intensity will be low, and it will become difficult, so we have to move very quickly."
"If the disease gets to a very low level, maybe challenge studies will have to be considered.
So-called human challenge trials have been discussed as an alternative option by scientists, whereby vaccinated volunteers are infected intentionally.
"We are running against time. We are seeing already in Europe the disease is declining," Soriot told an online press briefing. "Very soon the disease intensity will be low, and it will become difficult, so we have to move very quickly."
"If the disease gets to a very low level, maybe challenge studies will have to be considered.
Soriot said some of the Oxford University team that started early-stage human trials of the vaccine in April to test for safety and signs of an immune response were already privy to initial results, and that publication was imminent.
"We should see the results very soon," Soriot said.